Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 363

Similar articles for PubMed (Select 20393185)

2.

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.

Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R.

Cancer Res. 2007 May 1;67(9):4278-86.

3.

The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.

Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros LJ, Szankasi P, Elenitoba-Johnson KS.

Blood. 2009 Aug 20;114(8):1585-95. doi: 10.1182/blood-2009-02-204735. Epub 2009 Jun 16.

4.

Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).

Ouyang T, Bai RY, Bassermann F, von Klitzing C, Klumpen S, Miething C, Morris SW, Peschel C, Duyster J.

J Biol Chem. 2003 Aug 8;278(32):30028-36. Epub 2003 May 14.

5.

Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.

Cussac D, Greenland C, Roche S, Bai RY, Duyster J, Morris SW, Delsol G, Allouche M, Payrastre B.

Blood. 2004 Feb 15;103(4):1464-71. Epub 2003 Oct 16.

6.
8.

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G.

Blood. 2009 Mar 19;113(12):2776-90. doi: 10.1182/blood-2008-06-161018. Epub 2008 Oct 9.

9.

The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.

Horie R, Watanabe M, Ishida T, Koiwa T, Aizawa S, Itoh K, Higashihara M, Kadin ME, Watanabe T.

Cancer Cell. 2004 Apr;5(4):353-64.

10.

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.

Cancer Res. 2006 Jul 1;66(13):6589-97.

12.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

13.
14.

Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.

Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R.

Blood. 2006 Oct 15;108(8):2796-803. Epub 2006 Jul 6.

15.

The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intracellular domain of the surface receptor CD30 but is not activated by CD30 stimulation.

Hübinger G, Scheffrahn I, Müller E, Bai R, Duyster J, Morris SW, Schrezenmeier H, Bergmann L.

Exp Hematol. 1999 Dec;27(12):1796-805.

PMID:
10641597
16.
18.

Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry.

Wu F, Wang P, Young LC, Lai R, Li L.

Am J Pathol. 2009 Feb;174(2):361-70. doi: 10.2353/ajpath.2009.080521. Epub 2009 Jan 8.

19.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk